MarkERobsonMD

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Chief, Breast Medicine Service Attending Physician, Breast Medicine & Clinical Genetics; Member, Memorial Sloan-Kettering Cancer Center; Professor of Medicine, Weill Cornell Medical College

Request Appointment

Overview of Dr. Robson

Dr. Mark Robson is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from University of Virginia School of Medicine and has been in practice 31 years. Dr. Robson accepts several types of health insurance, listed below. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Book by Phone+1(520) 314-3703

Education & Training

National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1989 - 1992
National Capital ConsortiumResidency, Internal Medicine, 1986 - 1989
University of Virginia School of MedicineClass of 1986

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1996 - 2026
NJ State Medical License 2019 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Clinical Outcomes in Hereditary Cancer Start of enrollment: 2006 Jan 01
Withdrawn
Adherence to Intensive Surveillance for Hereditary Breast Cancer Start of enrollment: 2003 May 01
Completed
Peptide Profiles of Women Undergoing Breast Biopsy Start of enrollment: 2006 Jan 01
Completed
Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer Start of enrollment: 1999 Jul 01
Active, not recruiting
Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer Start of enrollment: 2011 Jun 28
Completed
A Safety Study Assessing the Effects of Receiving Genome Sequencing Results Start of enrollment: 2012 Sep 01
Completed
Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing Start of enrollment: 2013 Nov 01
Completed
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Start of enrollment: 2014 Mar 27
Active, not recruiting
Phase 3
Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer Start of enrollment: 2019 Apr 17
Recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1077 citations
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Colin C. Pritchard, Joaquin Mateo, Michael Walsh, Navonil De Sarkar, Wassim Abida
The New England Journal of Medicine. 2016-07-06
66 citations
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Zsofia K. Stadler, Anna Maio, Debyani Chakravarty, Yelena Kemel, Margaret Sheehan
Journal of Clinical Oncology. 2021-06-16
251 citations
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Bastien Nguyen, Christopher Fong, Anisha Luthra, Shaleigh A Smith, Renzo G DiNatale
Cell. 2022-02-03

Journal Articles

Toward Automation of Germline Variant Curation in Clinical Cancer Genetics
Steven Lipkin, Karen Cadoo, Mark Robson, Kenneth Offit, Liying Zhang, Zsofia Stadler, Diana Mandelker, Nature
Genome Doubling Shapes the Evolution and Prognosis of Advanced Cancers
Alison M Schram, Jose Baselga, Mark E Robson, David B Solit, Zsofia K Stadler, Nature
The Genomics ADvISER: Development and Usability Testing of a Decision Aid for the Selection of Incidental Sequencing Results
Jada G Hamilton, Mark Robson, Kenneth Offit, Nature

Lectures

Should Tumor-Normal Genomic Testing Be the Standard of Care in Oncology? Tumor Testing in Precision Oncology: From Heredity to Counseling to Implementation
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemot...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

A Phase IIA Trial of Acupuncture to Reduce Chemotherapy-Induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer PatientsAugust 2018

Press Mentions

What You Need to Know About Male Breast CancerOctober 10th, 2022
Genetic Tests for Breast Cancer Patients Create Treatment Opportunities — and ConfusionSeptember 20th, 2022
PARP Inhibitors in the Treatment of Breast Cancer: What’s Next?April 10th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California PPO
BCBS Illinois Blue Advantage HMO
BCBS Illinois HMO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Health Net California Large Group PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment